Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis - PubMed (original) (raw)

Sundeep Kumar Goyal et al. Indian J Gastroenterol. 2015 Jul.

Abstract

Background and aims: Limited data is available from India on outcome and efficacy of tenofovir and entecavir in hepatitis B virus (HBV)-related cirrhosis when used for prolonged time. We report the long-term efficacy and outcome of these antiviral drugs in patients with chronic HBV infection, with compensated or decompensated cirrhosis.

Methods: We retrospectively analyzed laboratory and clinical data of 400 HBV-related cirrhotic patients without access to liver transplantation, who were treated with tenofovir/entecavir therapy, from January 2007 to January 2014. Two hundred and ten (52.5 %) patients had at least one of the components of decompensation at baseline. Two hundred and twenty (55 %) and 180 (45 %) patients were initiated tenofovir and entecavir, respectively. Follow up period was 45 (12-68) months for tenofovir and 36 (11-60) months for entecavir.

Results: At the end of 1 year, levels of HBV DNA <20 IU/mL were achieved in 91.8 % and 88.8 % of patients, and alanine aminotransferase normalized in 54.5 % and 55.5 % of patients who received tenofovir and entecavir, respectively. At the last visit, Child-Turcotte-Pugh scores improved among 29.5 % of patients who received tenofovir, 25 % of those who received entecavir, and remained stable in 61.9 % and 65 % patients, respectively, in both groups. The 5-year cumulative rate of liver decompensation, hepatocellular carcinoma, and cirrhosis-related complications were 3.1 %, 1.9 %, and 2.1 % with an annual incidence of 0.8 %, 0.3 %, and 0.5 % per person-year, respectively.

Conclusion: Tenofovir and entecavir were effective and potent drugs for prolonged treatment of HBV cirrhosis and improved the overall clinical course.

Keywords: Antiviral; Chronic hepatitis B; Hepatitis B Virus; Hepatocellular carcinoma; Liver Cirrhosis; Liver decompensation; Liver fibrosis; Ultrasonography.

PubMed Disclaimer

References

    1. Hepatology. 2010 Sep;52(3):886-93 - PubMed
    1. Hepatology. 2003 Dec;38(6):1419-27 - PubMed
    1. Liver Transpl. 2008 Oct;14 Suppl 2:S1-7 - PubMed
    1. Clin Gastroenterol Hepatol. 2013 Jan;11(1):88-94 - PubMed
    1. Lancet. 2013 Feb 9;381(9865):468-75 - PubMed

MeSH terms

Substances

LinkOut - more resources